Now the FDA Wants Nalmefene to Be a Fentanyl-Exposure “Prophylactic”

Now the FDA Wants Nalmefene to Be a Fentanyl-Exposure “Prophylactic”

The Food and Drug Administration is reportedly providing guidance and “positive feedback” for a proposed nalmefene product that will last 24 hours, designed for military and first responders to self-administer as a precaution against secondhand fentanyl exposure. TH104 is being developed by Tharimmune, a blockchain-focused digital finance company with a biotech research arm that consists of basically just this product. The company announced Nove…

Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids

RED BANK, N.J., Nov. 13, 2025 /PRNewswire/ -- Tharimmune, Inc. (Nasdaq: THAR) ("Tharimmune" or the "Company"), a digital asset treasury company with a clinical-stage biotechnology function, today announced an update from the biotechnology side of the business. Its lead clinical…